Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elritercept - Keros Therapeutics

Next Previous
Drug Profile

Elritercept - Keros Therapeutics

Alternative Names: HS-20106; KER-050; RKER-050; TAK-226

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Keros Therapeutics
  • Developer Keros Therapeutics; Takeda
  • Class Antianaemics; Antithrombotics; Cardiovascular therapies; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Advanced glycosylation end product modulators; Erythropoiesis stimulants; Transforming growth factor beta inhibitors; Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Phase II Myelofibrosis
  • Preclinical Left ventricular hypertrophy
  • No development reported Duchenne muscular dystrophy; Facioscapulohumeral muscular dystrophy; Thrombocytopenia

Most Recent Events

  • 30 Jun 2025 Phase-III clinical trials in Anaemia in United Kingdom, Sweden, Poland, Lithuania, Italy, Hungary, Bulgaria, Brazil, Germany, Israel, Spain (SC) (NCT06499285)
  • 08 Feb 2025 Phase-III clinical trials in Anaemia in European Union (SC) prior to February 2025 (Takeda Pipeline, February 2025)
  • 08 Feb 2025 Phase-III clinical trials in Anaemia in Japan (SC) prior to February 2025 (Takeda Pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top